[Skip to Content]
[Skip to Content Landing]
The Cutting Edge
April 1, 2008

Successful Treatment With Etanercept of von Zumbusch Pustular Psoriasis in a Patient With Human Immunodeficiency Virus

Author Affiliations
 

MICHAEL P.HEFFERNANMDCHRISTIEAMMIRATIMD

Arch Dermatol. 2008;144(4):453-456. doi:10.1001/archderm.144.4.453

Treatment of von Zumbusch pustular psoriasis is a formidable task, especially when confounded by concomitant human immunodeficiency virus (HIV) infection. To our knowledge, this is the first report of successful use of a biologic agent to treat a patient with both von Zumbusch pustular psoriasis and HIV. Given the propensity of HIV to both trigger and exacerbate psoriasis and the potentially severe complications associated with the acute, von Zumbusch variant, we believe this report provides precedence for dermatologists to consider anti–tumor necrosis factor α (anti–TNF-α) agents as a part of the armamentarium in the treatment of these patients.

REPORT OF A CASE

A 32-year-old man with a history of HIV, psoriasis, and psoriatic arthritis presented with increased joint pain, widespread pruritic pustules, erythema, and intermittent fever with leukocytosis of 2 weeks’ duration (Figure 1 and Figure 2). The patient had an 11-year history of HIV infection (CD4 cell count, 435/μL; nadir, 200/μL; viral load, <75/μL). He was prescribed lamivudine plus zidovudine, tenofovir disoproxil fumarate, and atazanavir sulfate and had taken no new medications within 6 months prior to presentation. The topical regimen of clobetasol propionate ointment, the superpotent corticosteroid he had been using twice daily to control his plaque psoriasis, failed to alleviate the eruption. In addition, his arthritis became so severe that he was unable to accomplish activities of daily living without assistance. Findings from a biopsy sample of lesional skin demonstrated psoriasiform epidermal hyperplasia with intraepidermal pustules, pustules in the cornified layer, parakeratosis, and a superficial and midperivascular lymphocytic infiltrate most consistent with a diagnosis of pustular psoriasis.

Figure 1.
Patient at presentation, prior to treatment, showing widespread patches of erythema with overlying pustules affecting 90% of his body surface.

Patient at presentation, prior to treatment, showing widespread patches of erythema with overlying pustules affecting 90% of his body surface.

Figure 2.
Closeup of the patient at presentation showing numerous pinpoint pustules over a background of erythema.

Closeup of the patient at presentation showing numerous pinpoint pustules over a background of erythema.

CLINICAL CHALLENGE

Von Zumbusch pustular psoriasis is a severe, acutely generalized form of psoriasis associated with systemic complications such as leukocytosis, fever, arthropathy, congestive heart failure, and infection.1 Although in many patients the etiology is unknown, common triggers include withdrawal of systemic steroids, infections, drugs, and hypocalcemia.2 It is notoriously recalcitrant to treatment and may be life threatening.3 Current therapeutic modalities such as acitretin, cyclosporine, methotrexate, and phototherapy, or a combination of these, are often insufficient to achieve lasting remissions.4 In the recent literature, there have been several reports1,49 of successful treatment of generalized pustular psoriasis with anti–TNF-α agents (Table 1). Use of immunomodulatory medications in HIV patients, however, is tempered by concerns of increasing the risk of opportunistic infections, sepsis, and progression to AIDS.10 To our knowledge, there are no reports in the literature regarding use of biologic agents in HIV patients with generalized pustular psoriasis.

Table 1. 
Reports of Anti–TNF-α Therapy in Patients With Pustular Psoriasis
Reports of Anti–TNF-α Therapy in Patients With Pustular Psoriasis
SOLUTION

A MEDLINE search produced 2 case reports,11,12 1 case series,13 and 1 clinical trial14 pertaining to the use of etanercept, and 3 case reports1517 documenting the use of infliximab in HIV patients (Table 2). Although the available data are limited, it has been speculated that administration of biologic agents that block TNF-α in HIV patients does not adversely affect morbidity and mortality.10 Owing to the severity of disease and concomitant disabling arthritis that our patient was experiencing, we initiated therapy with etanercept at a dosage of 50 mg subcutaneously weekly after obtaining a negative purified protein derivative (PPD) test and a normal chest radiograph. Within 4 weeks, the patient achieved complete remission of his skin lesions, resolution of his fevers and joint pain, and normalization of his white blood cell count (Figure 3).

Figure 3.
Patient after 4 weeks of treatment with etanercept, 50 mg subcutaneously per week, showing complete resolution of the skin lesions.

Patient after 4 weeks of treatment with etanercept, 50 mg subcutaneously per week, showing complete resolution of the skin lesions.

Table 2. 
Reports of Anti–TNF-α Therapy in Patients With HIV
Reports of Anti–TNF-α Therapy in Patients With HIV

As of his most recent follow-up visit, 20 weeks after the initiation of therapy, the patient remained entirely free of pustular lesions and arthritic symptoms but had developed some recurrence of his plaque psoriasis. His CD4 cell count had increased to 633/μL, the viral load remained undetectable, and he had negative findings from a repeated PPD test. Furthermore, he had experienced no infections requiring antibiotic administration during the 20-week treatment period. With maintained remission of his generalized pustular psoriasis and psoriatic arthritis, the patient refused additional topical corticosteroid treatment of his plaque lesions and continued to be prescribed etanercept alone. Although his acute flare of generalized pustular psoriasis, its associated systemic symptoms, and his debilitating psoriatic arthritis improved dramatically with etanercept, 50 mg subcutaneously weekly, we suspect that additional treatment with a higher dose of etanercept, concomitant methotrexate, or another biologic agent will be needed to fully control his plaque psoriasis.

COMMENT

Dysregulation of the proinflammatory cytokine TNF-α is common to both von Zumbusch pustular psoriasis18 and HIV infection.19 The integral role of TNF-α in the pathogenesis of psoriasis and psoriatic arthritis is evidenced by the elevated levels detected in lesional skin20 and synovium,21 as well as by the therapeutic efficacy of biologic anti–TNF-α agents.22 Von Zumbusch pustular psoriasis is a hyperinflammatory, generalized form of psoriasis characterized by the appearance of widespread erythematous pustules with systemic involvement.3 Tumor necrosis factor α has been implicated in the pathogenesis through its role in the stimulation of granulocyte overactivation and tissue invasion9,18 that results in the formation of generalized erythematous pustules. There are few reports in the literature, however, documenting the use of anti–TNF-α agents in von Zumbusch pustular psoriasis.1,49

In terms of HIV, studies have shown that TNF-α stimulates viral replication in vitro23 and may also contribute to development of aphthous ulcers, fatigue, lipodystrophy,19,24 fever, and dementia.25,26 These data have led several researchers to suggest that HIV treatment should include blockade of TNF-α,10 making it an attractive target in HIV patients with severe and generalized pustular psoriasis.

We describe an HIV patient with von Zumbusch pustular psoriasis and severe psoriatic arthritis who had a dramatic response to etanercept, 50 mg subcutaneously weekly. This is the first report, to our knowledge, of successful treatment of a patient with both HIV and von Zumbusch pustular psoriasis using an anti–TNF-α agent. Given the propensity of HIV infection to both trigger and exacerbate psoriasis27 and the potentially severe complications associated with the acute, von Zumbusch variant, anti–TNF-α agents should be used cautiously as part of our armamentarium in the treatment of these patients.

Box Section Ref ID

Submissions

Clinicians, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Manuscripts should be prepared double-spaced with right margins nonjustified. Pages should be numbered consecutively with the title page separated from the text (see Instructions for Authors [http://archderm.ama-assn.org/misc/ifora.dtl] for information about preparation of the title page). Clinical photographs, photomicrographs, and illustrations must be sharply focused and submitted as separate JPG files with each file numbered with the figure number. Material must be accompanied by the required copyright transfer statement (see authorship form [http://archderm.ama-assn.org/misc/auinst_crit.pdf]). Preliminary inquiries regarding submissions for this feature may be submitted to George J. Hruza, MD (ghruza@aol.com). Manuscripts should be submitted via our online manuscript submission and review system (http://manuscripts.archdermatol.com).

Back to top
Article Information

Correspondence: Barry L. Smith, MD, Department of Dermatology, St Luke’s–Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025 (Smith1194@aol.com).

Accepted for Publication: June 14, 2007.

Author Contributions: Drs Mikhail, Weinberg, and Smith have reviewed the manuscript and take full responsibility for the accuracy of the data. Study concept and design: Weinberg and Smith. Acquisition of data: Smith. Analysis and interpretation of data: Mikhail, Weinberg, and Smith. Drafting of the manuscript: Mikhail. Critical revision of the manuscript for important intellectual content: Weinberg and Smith. Administrative, technical, and material support: Mikhail and Smith. Study supervision: Weinberg and Smith.

Financial Disclosure: Dr Weinberg holds research grants funded by Amgen and Abbott and is a member of the Abbott and Amgen speakers bureau.

References
1.
Trent  JTKerdel  FA Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004;8 (4) 224- 228
PubMedArticle
2.
Baron  ETCharles  RT Pustular psoriasis. http://www.emedicine.com/derm/topic366/htm. Accessed June 2007
3.
Umezawa  YOzawa  AKawasima  T  et al.  Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003;295 ((suppl 1)) S43- S54
PubMedArticle
4.
Weisenseel  PPrinz  JC Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 2006;78 (3) 197- 199
PubMed
5.
Benoit  SToksoy  ABrocker  EBGillitzer  RGoebeler  M Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004;150 (5) 1009- 1012
PubMedArticle
6.
Newland  MRWeinstein  AKerdel  F Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41 (7) 449- 452
PubMedArticle
7.
Elewski  BE Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47 (5) 796- 797
PubMedArticle
8.
Lewis  TGTuchinda  CLim  HWWong  HK Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol 2006;5 (6) 546- 548
PubMed
9.
Schmick  KGrabbe  J Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 2004;150 (2) 367
PubMedArticle
10.
Ting  PTKoo  JY Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006;45 (6) 689- 692
PubMedArticle
11.
Aboulafia  DMBundow  DWilske  KOchs  UI Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000;75 (10) 1093- 1098
PubMedArticle
12.
Kaur  PPChan  VCBerney  SN Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007;13 (2) 79- 80
PubMedArticle
13.
Sha  BEValdez  HGelman  RS  et al.  Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002;18 (9) 661- 665
PubMedArticle
14.
Wallis  RSKyambadde  PJohnson  JL  et al.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18 (2) 257- 264
PubMedArticle
15.
Gaylis  N Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003;30 (2) 407- 411
PubMed
16.
Bartke  UVenten  IKreuter  AGubbay  SAltmeyer  PBrockmeyer  NH Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab [published correction appears in Br J Dermatol. 2004;150(6):1235]. Br J Dermatol 2004;150 (4) 784- 786
PubMedArticle
17.
Sellam  JBouvard  BMasson  C  et al.  Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007;74 (2) 197- 200
PubMedArticle
18.
Iizuka  HTakahashi  HIshida-Yamamoto  A Pathophysiology of generalized pustular psoriasis. Arch Dermatol Res 2003;295 ((suppl 1)) S55- S59
PubMed
19.
Drexler  AM Tumor necrosis factor: its role in HIV/AIDS. STEP Perspect 1995;7 (1) 13- 15
PubMed
20.
Ettehadi  PGreaves  MWWallach  DAderka  DCamp  RD Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96 (1) 146- 151
PubMedArticle
21.
Ritchlin  CHaas-Smith  SAHicks  DCappuccio  JOsterland  CKLooney  RJ Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25 (8) 1544- 1552
PubMed
22.
Weinberg  JMBottino  CJLindholm  JBuchholz  R Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J Drugs Dermatol 2005;4 (5) 544- 555
PubMed
23.
Ito  MBaba  MSato  A  et al.  Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989;158 (1) 307- 312
PubMedArticle
24.
Haugaard  SBAndersen  OPedersen  SB  et al.  Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006;55 (2) 175- 182
PubMedArticle
25.
Fine  SMMaggirwar  SBElliott  PREpstein  LGGelbard  HADewhurst  S Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. J Neuroimmunol 1999;95 (1-2) 55- 64
PubMedArticle
26.
Seilhean  DKobayashi  KHe  Y  et al.  Tumor necrosis factor-alpha, microglia and astrocytes in AIDS dementia complex. Acta Neuropathol 1997;93 (5) 508- 517
PubMedArticle
27.
Chen  TCockerell  C Cutaneous manifestations of HIV and HIV-related disorders. Bolognia  JJorizzo  JRapini  RDermatology. London, England Elsevier2003;1199- 1215
×